← All compounds
peptide23 listings
PT-141
Bremelanotide
Melanocortin receptor agonist. Studied in melanocortin signaling research.
Melanocortin research
/ research index
The research base
Research Maturity
★★★☆☆
3/5 — Volume of studies
Evidence Strength
★★★☆☆
3/5 — Quality of evidence
Multiple Phase 2/3 trials. FDA approved for specific research applications.
/ mechanism of action
How it works
Melanocortin-4 receptor (MC4R) agonist.
/ research dosing
Common research protocols
Range
0.5-2 mg per dose (typical: 1-1.75 mg)
Frequency
As needed, 1-3 hours before activity
Route
Subcutaneous or intranasal
Cycle
PRN, not daily
Research notes
Bremelanotide — FDA-approved as Vyleesi at 1.75mg subQ for HSDD in women. Higher doses (2mg+) increase side effects (nausea, BP). Onset 30-60 min, duration 4-6 hours. Not for daily use.
References
FDA Vyleesi labelPMID: 18774751 →
FOR RESEARCH USE ONLY. Doses listed are compiled from published research literature, FDA-approved drug labels, and well-documented research community practice. Not medical advice.
/ standalone use
As a solo compound
Designed for solo use in research.
/ side effects
What to know
Common: facial flushing, mild nausea.
/ timeline
Realistic expectations
Effects within hours of administration
/ recommendation
Where to buy PT-141
🏆Our pick for PT-141
Ascension Peptides
10mg · USA · Card / Crypto / Zelle
- ✓Third-party tested (Janoshik)
- ✓COAs provided — Per-batch core, quarterly bonus
- ✓Within 4% of cheapest, higher verification tier
- ✓4.8★ community rating
Also solid
/ all listings
Full index, price per mg
Supplier
Trust Score
Size
Price
$/mg
Stock
Buy
FOR RESEARCH USE ONLY. PT-141 is intended for laboratory research and not for human consumption.